Department of Neurology, Stroke Program, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA.
Expert Rev Neurother. 2012 Feb;12(2):179-89; quiz 190. doi: 10.1586/ern.11.185.
Stroke is a leading cause of cardiovascular morbidity and mortality worldwide. Approximately, 795,000 strokes occur in the USA each year, 610,000 of which are first events, and 185,000 of which are recurrent events. Of all strokes, 87% are ischemic strokes. Novel anticoagulants serve as an alternative antithrombotic intervention in patients with ischemic cerebrovascular disease. This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation.
中风是全世界心血管发病率和死亡率的主要原因。 每年在美国约有 795,000 例中风，其中 610,000 例为首发事件，185,000 例为复发事件。 在所有中风中，87%为缺血性中风。 新型抗凝剂可作为缺血性脑血管疾病患者的另一种抗血栓干预措施。 本文综述了新型抗凝剂达比加群、利伐沙班和阿哌沙班在非瓣膜性心房颤动患者中风预防中的作用。
